Windorphen
(Synonyms: 3-氯-2,3-双(4-甲氧苯基)丙烯醛) 目录号 : GC12133
Wnt inhibitor
Cas No.:19881-70-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Windorphen is a Wnt inhibitor that selectively abrogates the Wnt signaling for ventral development.
Wnt protein is a family of signaling proteins that interacts on the Wnt/β-Catenin pathways during embryotic development, cell proliferation, migration and adult tissue homeostasis.
In canonical Wnt/β-catenin reporter cell line STF293, Windorphen dose-dependently inhibits Wnt3a-inducible TOPFLASH-luciferase activity (IC50 of 1.5 mM). In human colon adenocarcinoma
SW480 cells with defective APC gene that constitutively activates Wnt signaling, 72 h treatment of Windorphen causes a wide spread apoptosis. [1]
In zebrafish embryos, Windorphen leads to apparent expansion of the dorsal markers (pax2.1) and marker of rhombomeres 3 and 5 at the six-somite stage (krox0). Windorphen selectively inhibits Wnt signaling in ventral and lateral regions of the 50% epiboly stage embryo (5.3 hpf). In addition, Windoprhen treatment rescues the telencephalon/eye phenotype in the mbl mutant zebrafish (i.e. a defective Axin1/β-catenin destruction complex causes abnormal activation of Wnt signaling and the loss of telencephalon and eyes.) [1]
Reference:
1. Hao J, Ao A, Zhou L et al. Selective small molecule targeting β-catenin function discovered by in
vivo chemical genetic screen. Cell Rep. 2013 Sep 12;4(5):898-904.
| Cas No. | 19881-70-0 | SDF | |
| 别名 | 3-氯-2,3-双(4-甲氧苯基)丙烯醛 | ||
| 化学名 | (E)-3-chloro-2,3-bis(4-methoxyphenyl)acrylaldehyde | ||
| Canonical SMILES | O=C/C(C1=CC=C(OC)C=C1)=C(Cl)\C2=CC=C(OC)C=C2 | ||
| 分子式 | C17H15ClO3 | 分子量 | 302.75 |
| 溶解度 | ≥ 11.45mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.3031 mL | 16.5153 mL | 33.0306 mL |
| 5 mM | 0.6606 mL | 3.3031 mL | 6.6061 mL |
| 10 mM | 0.3303 mL | 1.6515 mL | 3.3031 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet